Conference Coverage

ASCO: Omitting adjuvant radiation after pCR ups locoregional recurrence risk


 

AT THE 2015 ASCO ANNUAL MEETING

References

Multivariate analysis here again showed that radiation therapy independently predicted better locoregional recurrence–free survival (HR, 0.56; P = .029) but not disease-free survival.

Pages

Recommended Reading

VIDEO: Palbociclib may delay chemotherapy for some women with metastatic breast cancer
MDedge Hematology and Oncology
CDK inhibitor remains active as endocrine resistance emerges
MDedge Hematology and Oncology
Anastrozole provides alternative option for DCIS
MDedge Hematology and Oncology
ASCO: Adjuvant neratinib has payoff in HER2-positive breast cancer
MDedge Hematology and Oncology
ASCO: Precision medicine initiatives take wing
MDedge Hematology and Oncology
Three bisphosphonates found on par in early breast cancer
MDedge Hematology and Oncology
VIDEO: Dr. William J. Gradishar provides take-home messages from ASCO 2015
MDedge Hematology and Oncology
ASCO: Enzalutamide advances in triple-negative breast cancer
MDedge Hematology and Oncology
Advanced breast cancer: paclitaxel bests nab-paclitaxel, ixabepilone
MDedge Hematology and Oncology
David Henry's JCSO podcast, May 2015
MDedge Hematology and Oncology